Full-Time

Scientist – Immunology

Discovery Research

Confirmed live in the last 24 hours

Generation Bio

Generation Bio

51-200 employees

Develops durable genetic treatments for diseases

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Experience in the fields of immunology or cell biology (or related)
  • PhD, MS with a minimum of 6 years of related experience, or BS with a minimum of 8 years of related experience, industry experience preferred.
  • Demonstrated leadership and hands on experience in primary immune cell assay development and execution
  • Experience isolating and culturing primary immune cells, such as T cells and B cells from human and/or mouse required
  • Experience with T cell assays (such as T cell activation and differentiation)
  • Knowledge of flow cytometry and multi-color panel design strongly desired
  • Experience with QPCR, western blot techniques, ELISAs, etc a plus
  • Ability to work cross functionally in a dynamic matrixed environment
  • Ability to multi-task to support multiple projects across platform discovery organization
  • Organized, excellent communication skills, collaborative mindset
Responsibilities
  • Contribute to the design, optimization and execution of assays to assess ctLNP interactions with primary immune cells
  • Work with Preclinical Group to evaluate novel ctLNPs and target biologies for new platform technologies
  • Perform a range of biochemical techniques such as ELISA, MSD, qPCR and flow cytometry to characterize protein and RNA expression and function.
  • Design experiments, analyze data and interpret results
  • Summarize work in written reports and oral presentations
  • Maintain accurate and up-to-date laboratory records

Generation Bio focuses on developing genetic treatments for both rare and common diseases. Their main product is based on a non-viral genetic medicine platform that includes iqDNA, which is designed to be immune-quiet, and ctLNP, a delivery system that targets specific cells. This platform allows for the creation of treatments that can last for several years from a single dose and can be adjusted for patient needs through redosing. They use a unique manufacturing process called rapid enzymatic synthesis (RES) that enables them to produce large quantities of their genetic medicine efficiently. Unlike many competitors, Generation Bio aims to make these treatments widely accessible by scaling production to meet high demand. The company's goal is to address significant medical needs by providing durable and effective genetic therapies.

Company Stage

IPO

Total Funding

$252.9M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

-2%

1 year growth

-25%

2 year growth

-18%
Simplify Jobs

Simplify's Take

What believers are saying

  • The development of iqDNA and ctLNP platforms positions Generation Bio at the forefront of genetic medicine innovation, potentially leading to breakthrough treatments for rare and prevalent diseases.
  • Strategic reorganization and cost-saving measures extend the company's cash runway into the second half of 2027, providing financial stability and continued investment in R&D.
  • High-profile presentations at conferences and collaborations with industry leaders like Moderna enhance the company's visibility and credibility in the biotech sector.

What critics are saying

  • The 40% workforce reduction as part of the strategic reorganization could impact employee morale and productivity.
  • Dependence on successful integration and advancement of iqDNA and ctLNP platforms carries inherent risks if the technologies do not perform as expected in clinical settings.

What makes Generation Bio unique

  • Generation Bio's focus on non-viral genetic medicines using proprietary immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms sets it apart from traditional gene therapy companies.
  • Their scalable capsid-free manufacturing process, utilizing rapid enzymatic synthesis (RES), offers a unique advantage in producing genetic medicines efficiently.
  • The strategic collaboration with Moderna highlights Generation Bio's innovative approach and industry recognition.

Help us improve and share your feedback! Did you find this helpful?